15 results about "Drug targetting" patented technology

This invention relates to the field of nanomedicine delivery systems, specifically to an ultrasound-enhanced synergistic immunotherapy drug delivery system, its preparation method, and its applications. The ultrasound-enhanced synergistic immunotherapy drug delivery system includes a lipid shell and a fluorocarbon gas encapsulated within the lipid shell. The lipid shell is made from cancer cell membranes and a lipid membrane formed from synthetic phospholipids. The lipid shell integrates a protein degradation-targeting chimera for degrading PD-L1. This invention combines targeted drug delivery, PD-L1 targeted degradation, and ultrasound enhancement technology to construct an integrated synergistic immunotherapy drug delivery system. Through multi-mechanism synergistic action, it overcomes the bottlenecks of existing PROTAC delivery systems, achieving a highly efficient anti-tumor immune response. This technical solution solves the technical problems of limited tumor tissue penetration and cellular uptake efficiency of PROTAC degrading agents targeting PD-L1, resulting in unsatisfactory delivery effects and promising prospects for widespread application.

The application provides a drug delivery system for targeted treatment of inflammatory diseases and a preparation method and application thereof, and belongs to the technical field of biological drugs. The drug delivery system for targeted treatment of inflammatory diseases is M2 type macrophages phagocytizing drug-loaded nanoparticles, wherein the drug-loaded nanoparticles comprise a biodegradable high molecular material for coating drugs. The drug delivery system prepared by the application realizes lung targeted delivery through the natural inflammatory chemotaxis characteristics of M2 type macrophages, and in combination with the drug slow-release effect of the drug-loaded nanoparticles, the drug targeting and availability are significantly improved, so that the drug efficacy is improved, the biological safety is good, and a new effective means is provided for the clinical treatment of various inflammatory diseases including carbapenem-resistant Klebsiella pneumoniae (CRKP) pneumonia.

The application belongs to the technical field of biomaterial preparation, and particularly relates to a composite drug delivery system based on macrophage membranes and a preparation method and application thereof. The composite drug delivery system takes a lipid nanoparticle as a drug targeting delivery carrier, coats quercetin through an active phagocytosis mode, coats a macrophage membrane on the surface of the lipid nanoparticle, and constructs a quercetin lipid nanoparticle coated with a macrophage membrane (MCM@QU@LNP). The composite drug delivery system provided by the application can promote drug enrichment in RA lesions, improve local drug exposure, realize precise drug delivery in the RA part, has good biological safety, and reduces system toxicity.

This invention discloses an injectable hydrogel loaded with 4-octyl itaconic acid, its preparation method, and its applications, belonging to the field of biomedical materials technology. The injectable hydrogel is formed by enzymatic cross-linking of a hyaluronic acid-tyramine complex to create a three-dimensional network, with 4-octyl itaconic acid encapsulated within this network structure. This invention allows for precise implantation of the hydrogel into the intervertebral disc lesion via minimally invasive injection, achieving local high-concentration drug accumulation. The three-dimensional network of the hydrogel serves as a drug reservoir, enabling continuous and controllable release of 4-OI, prolonging the drug's duration of action and achieving long-term therapeutic effects. Simultaneously, the loaded 4-OI specifically activates the Nrf2 / GPX4 antioxidant pathway in nucleus pulposus cells, mechanistically antagonizing ferroptosis and matrix degradation, thus achieving a dual function of mechanical support and biological therapy. It exhibits good biocompatibility and solves the problems of difficult targeted drug delivery, short-lived efficacy, and lack of disease-modifying effects in existing treatments for intervertebral disc degeneration.

The application belongs to the technical field of biological medicine, and discloses a kind of construction and application of biologic macromolecule gel microspheres that can be assembled.The application discloses a kind of gel microspheres, including gel microsphere 1 and / or gel microsphere 2.The application provides a kind of gel microspheres, which are delivered to pathological sites by the specific targeting effect of fucoidan on damaged endothelial cells.Further, gel microsphere 1 and gel microsphere 2 overcome the limitation of steric hindrance by supramolecular assembly between adamantane and cyclodextrin, provide more drug targeting anchor points, thereby improving the drug concentration at the pathological site to enhance the therapeutic efficacy of IBD.The assembly strategy of the gel microspheres provides an effective method for enhancing the drug concentration of micron-sized oral drugs at the pathological site, and provides a new idea for the delivery of micron-sized oral drugs.

Disclosed herein are implantable intraocular drug delivery devices structured to provide targeted and / or controlled release of a drug to a desired intraocular target tissue, and methods of implanting and methods of using such devices for the treatment of ocular diseases and disorders. In certain embodiments, some, most, or essentially all of the device is made of biodegradable materials.

The present disclosure pertains to a medical device, system, and method for targeted delivery of medical agents to specific locations within the vascular system. The system features an intravascular device comprising a tubular body having an inner lumen for maintaining antegrade blood flow and at least two inflatable annular members spaced along the tubular body. The annular members are configured to expand radially to define a confined treatment zone within the vessel, thereby enabling localized administration of medical agents while preserving physiological blood flow. The system further features a delivery system that includes a multi-lumen shaft configured to facilitate controlled inflation of the annular members and administration of the medical agents. In addition, the present disclosure pertains to a method of delivering medical agents to a targeted vascular location by advancing the intravascular device to the target site, inflating the annular members to form the confined treatment zone, and administering the agents through the multi-lumen shaft under predetermined pressure and flow conditions. Accordingly, the described technology enhances treatment precision and reduces systemic exposure of the medical agents in applications including tumor therapy, aneurysm, plaque and thrombus management.

The application provides a polypeptide molecule for specifically recognizing HIV gp120 protein and an application thereof, and belongs to the technical field of biological medicine. The application provides a lead polypeptide derivative for specifically targeting and combining HIV gp120, wherein the lead polypeptide comprises an amino acid sequence shown in SEQ ID No. 1. The application also provides a lead polypeptide derivative prepared based on the lead polypeptide, and a polypeptide nanoparticle constructed by the lead polypeptide derivative, and both of them have gp120 protein combining capacity. The derivative and the nanoparticle have good virus neutralization inhibition effect. The series of polypeptide molecules can specifically combine with free HIV virus, HIV infected cells and free gp120, so as to block HIV infected cells, delay the AIDS disease process, realize AIDS treatment drug targeted delivery, detection and diagnosis.

This invention relates to the field of pharmaceutical technology, specifically to a biomimetic nanodelivery system (LLip@PC-GHRK) encapsulated in an MMP-9 / pH dual-responsive fusion membrane, its preparation method, and its applications. The outer layer of this nanocomposite system is a biomimetic membrane LLip fused with tumor cell membranes and liposomes, promoting efficient uptake of biomimetic nanomedicines by tumor cells. The middle layer is coated with pH-responsive units, enabling charge-flipping molecules PLL-CA (PC) to prevent drug degradation in lysosomes. The core is a multifunctional self-assembled polypeptide carrier integrating pH-responsive peptides, cell-penetrating peptides, and nuclear-localizing peptides, capable of loading gene-based drugs. This biomimetic nanodelivery system exhibits good biocompatibility and significantly improves targeted drug delivery efficiency and efficacy through tumor homology targeting, tumor microenvironment responsive activation, and programmed drug release, providing a novel intelligent delivery paradigm for combination cancer therapy.

This invention belongs to the field of biomedical engineering and discloses a method for extracting exovesicles from Gram-positive bacteria. The method involves culturing Gram-positive bacteria to the logarithmic growth phase to remove residual culture medium components, and then obtaining bacterial exovesicles derived from Gram-positive bacteria through multiple freeze-thaw cycles. These exovesicles contain active substances from the bacteria, such as proteins and small RNA molecules, which can participate in regulating physiological metabolic processes in vivo. Furthermore, they can also serve as drug delivery carriers, crossing membrane systems to target receptor cells via membrane signaling molecules, achieving targeted drug release.

The application discloses an engineered exosome medicine for targeted degradation of TGF-beta, a preparation method and application, and the medicine comprises: a TGF-beta Trap protein which is used for competitively combining with TGF-beta; a membrane anchoring protein which is used for embedding the TGF-beta Trap protein and anchoring the TGF-beta Trap protein to the surface of an exosome membrane; and a targeted biological recognition molecule which is connected to the exosome through protein fusion or click chemistry reaction and is used for targeting the engineered exosome medicine to tumor cells. The engineered exosome medicine provided by the application is a medicine which can effectively block and remove TGF-beta, can effectively weaken systemic toxicity and off-target side effects, and avoids problems such as complexity of exosome in-vitro modification, batch difference, drug activity initiation and the like.

A drug delivery system based on sensitized mast cells, its preparation method, and its application are disclosed, along with a pharmaceutical composition and delivery device involving the sensitized mast cell delivery system. This delivery system utilizes the specific recognition of tumor antigens by sensitized mast cells to target and deliver drugs to tumor cells while protecting them from clearance by the circulating immune system. Upon activation by tumor antigens, sensitized mast cells rapidly degranulate to release the drug, thereby enhancing infection response, exerting an oncolytic effect, lysing tumor cells and releasing antigens, and activating an anti-tumor immune response. This delivery system can serve as a promising platform technology for personalized therapy.

The present application provides a kind of lysosome targeting three-dimensional network nanogel, its preparation method and application.The three-dimensional network nanogel of the present application includes: lysosome targeting drug and hyaluronic acid.The present application prepares lysosome targeting drug into hyaluronic acid nanogel, and utilizes nanogel to target drug delivery to lysosome in tumor cell.According to the difference of lysosome targeting drug used, can be in vivo intervention to lysosome homeostasis of tumor cell, realize leukemia differentiation therapy and other purposes.

This invention provides a functional plaster base fabric, belonging to the field of medical device technology. The base fabric is composed of one or more polymer films selected from polytetrafluoroethylene (PTFE), polyvinylidene fluoride (PVDF), and perfluoroethylene propylene copolymer (FEP), or further formed into a composite film with other materials. When the functional plaster base fabric is subjected to continuous external forces such as friction, patting, or pressing, it generates a Maxwell pulse electric field and pulsed current. Through the generated electric field and current, cells can be activated, blood circulation promoted, and local tissue temperature increased, thereby accelerating cell metabolism. When used in conjunction with the plaster, it produces a synergistic effect, enhancing drug absorption and improving the plaster's efficacy. Furthermore, this base fabric has targeting properties, guiding drugs precisely to the target area and effectively regulating drug release, making it particularly suitable for the treatment of tumors and cytopathic tumors. The functional plaster base fabric of this invention can be designed as a single-layer or multi-layer structure according to requirements. During the manufacturing process, the polymer film can be composited with other materials through processes such as hot pressing, bonding, and coating to ensure the structural stability and functional effectiveness of the base fabric. The functional plaster base fabric provided by this invention not only improves the therapeutic effect of plasters, but also provides a new solution for targeted drug therapy and the treatment of specific diseases.